Search & Analyze
Popular Searches
Dr. Reddy's Laboratories Ltd.
23 Oct, 4:01 PM
Customise metrics bar
Dr. Reddy's Laboratories Ltd. (DRREDDY) share price closed at ₹1,224.50 on the BSE on Friday, October 23, 2026, down by 1.17% from its of ₹1,239.00. In that session DRREDDY reached a of 1,251.00 and of 1,215.35. The for the session was 1,229.83. The stands at 1,192.55 and is at 1,243.17. Looking at , the stock ended the session in Downtrend.
Stock Overview
Symbol
DRREDDY
₹1,234.70
₹1,239.00
₹1,229.83
₹1,192.55
Price 2.68% above
₹1,243.17
Price 1.50% below
Price Performance
Peer Comparison
| Name | |||||||||
|---|---|---|---|---|---|---|---|---|---|
SUN PHARMA. SUNPHARMA | 1,743.00 | 34.58 | 4,18,204.09 | 0.92 | 2,901.23 | 26.53% | 15,299.88 | 10.46% | 19.11 |
DIVI'S LAB. DIVISLAB | 8,984.00 | 81.54 | 2,38,496.97 | 0.33 | 902.00 | 65.50% | 3,080.00 | 27.80% | 21.51 |
TORRENT PHAR TORNTPHARM | 4,482.00 | 80.26 | 1,70,480.87 | 0.85 | 534.00 | -9.64% | 4,979.00 | 50.79% | 19.27 |
ZYDUSLIFE ZYDUSLIFE | 1,127.85 | 24.93 | 1,12,503.47 | 0.09 | 990.20 | -34.90% | 8,017.00 | 21.96% | 21.39 |
CIPLA LTD. CIPLA | 1,337.00 | 32.04 | 1,08,012.30 | 0.97 | 785.55 | -39.18% | 7,119.28 | 2.33% | 16.00 |
LAURUSLABS LAURUSLABS | 1,974.00 | 97.55 | 1,06,657.63 | 0.10 | 362.07 | 123.94% | 2,026.31 | 29.10% | 18.20 |
Dr. Reddy's Laboratories Ltd. DRREDDY | 1,224.50 | 36.50 | 1,02,206.60 | 0.65 | 913.20 | -31.69% | 8,697.80 | -1.48% | 13.75 |
MANKIND MANKIND | 2,217.00 | 44.83 | 91,572.10 | 0.05 | 574.09 | 29.12% | 4,030.59 | 12.89% | 13.24 |
Quarterly Results
consolidated figures in ₹ Crores · Quarterly
Profit & Loss
consolidated figures in ₹ Crores · Annual
Balance Sheet
consolidated figures in ₹ Crores
Cash Flow
consolidated figures in ₹ Crores
Ratios
Valuation
Profitability
Leverage & Liquidity
Returns
Mutual Funds Invested(287)
Based on each fund's latest monthly portfolio · Sep 2026
A total of 135 active funds hold 11.54% in Dr. Reddy's Laboratories Ltd., contributing to ₹11.88K Cr of holdings
Corporate Actions
Insider Trading
Sector Overview
Dr. Reddy's Laboratories Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.
Company Profile
Corporate information and contact details
Company Information
Industry
Pharmaceuticals & Drugs
Founded
1984
Headquarters
Hyderabad, Telangana
Group
Dr. Reddy's
Chairman
K Satish Reddy
Managing Director
GV Prasad
Company Secretary
K Randhir Singh
Face Value
₹1
CIN
L85195TG1984PLC004507
Get in Touch
Key Management
14 members across the board and senior leadership
K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR
—
K Satish Reddy
Chairman
₹1.01 Cr
Mar '26
GV Prasad
Co-Chairman & Managing Director
₹1.58 Cr
Mar '26
GV Prasad
Co-Chairman & Managing Director
₹18.83 Cr
Mar '25
Leo Puri
Lead Independent Director
₹22.62 L
Mar '26
Arun Kumar
Non Executive Independent Director
₹22.14 L
Mar '26
Claudio Albrecht
Non Executive Independent Director
₹20.24 L
Mar '26
K P Krishnan
Non Executive Independent Director
₹17.40 L
Mar '26
Penny Wan
Non Executive Independent Director
₹20.72 L
Mar '26
Sanjiv Mehta
Non Executive Independent Director
₹17.40 L
Mar '26
Shikha Sharma
Non Executive Independent Director
₹16.45 L
Mar '26
Alpna Hansraj Seth
Non Executive Independent Director
₹1.78 Cr
Mar '25
Alpna Seth
Non Executive Independent Director
₹19.77 L
Mar '26
Srikanth Velamakanni
Independent Director
—
DRREDDY Latest News
News
10 of 10 articlesDr. Reddy’s Laboratories gets nod for Zytorvi in advanced esophageal cancer
The company entered into a licensing and commercialization agreement with Junshi Biosciences in 2023 for toripalimab across 21 countries
Dr. Reddy’s Laboratories informs about press release
USFDA completes pre-approval inspection at Dr. Reddy’s Visakhapatnam facility
The company has been issued a Form 483 with three observations
Dr. Reddy's Laboratories launches NIVORZ in India
The launch of NIVORZ further strengthens the company's oncology portfolio and expands its presence in immuno-oncology
Dr Reddys Laboratories informs about newspaper publication
USFDA completes GMP inspection at Dr. Reddy's manufacturing facility in Hyderabad
The inspection was conducted from August 6, 2026 to August 14, 2026
Dr. Reddy's Laboratories rises on getting USFDA’s approval for rituximab biosimilar
The approval further strengthens its growing global biosimilars portfolio and advances its biosimilars business in the United States
Dr. Reddy's Laboratories hits 52-week low as its consolidated net profit drops 69% in Q1
Consolidated total income of the company declined by 4.60% to Rs 8,454.50 crore in Q1FY27
Dr. Reddy's Laboratories’ consolidated net profit drops 69% in Q1
Consolidated total income of the company declined by 4.60% to Rs 8,454.50 crore in Q1FY27
Dr. Reddy’s Laboratories informs about audio recordings of earnings call
DRREDDY
₹1,224.50